The nextgeneration vaccine delivery system, created by vaxxas, is called the nanopatch and is the size of an adult thumbnail. All the authors are inventors on patents licenced to vaxxas. Vaxxas is a company based out of vaxxas pty ltd acn 152 205 242c oneventures management suite 304, level 3, 1 alfred street, sydney, nsw, australia. Invetech and vaxxas named recipients of the 2015 good design. Drycoated live viral vector vaccines delivered by nanopatch. Arc future fellow pioneers needlefree immunisation for the. Vaxxas biomedical expertise to boost griffith microtech. Involved in manufacturing of nanopatch and quality control. Oneventures invests in regional queensland company developing treatments for autoimmune diseases. Vaxxas, a brisbane, australiabased company, develops and commercializes needlefree vaccine delivery system. Influenza nucleoprotein dna vaccination by a skin targeted.
It uses thousands of vaccinecoated pins that perforate into the skin. How nanotech is changing your world world economic forum. The research and development under his future fellowship led to spinout company vaxxas. Vaxxas is a venture capital funded technology startup biotechnology company focused on enhancing the performance of existing and nextgeneration vaccines through its. Tri is home to many success stories including the vaxxas nanopatch, patented and commercialised from research completed at the university of queensland. Arc future fellow pioneers needlefree immunisation for. Vaxxas is a privatelyheld biotechnology company focused on enhancing the performance of existing and next generation vaccines with its proprietary nanopatchtm technology platform. Aug 30, 2012 nanopatch a new vaccination delivery method could replace needles and syringes and save millions of lives. Sep 16, 2014 vaxxas has just signed an agreement with the world health organisation who to trial its nanopatch delivery system for polio vaccines, which the company hopes will progress the technology through. Wt wearable technologies is the pioneer and worldwide leading innovation and market development platform for technologies worn close to the body, on the body or even in the body. Application of the nanopatch to the skin is designed to be pain free, rapidly delivering vaccine directly to the abundant.
Technology networks science events technology networks. Needlefree technology developed by the university of queensland has been used to successfully deliver an inactivated poliovirus vaccine. F are inventors on nanopatch patents licenced to vaxxas. Australian company vaxxas is pioneering a nextgeneration vaccine delivery platform called nanopatch, a microscopic patch that consists of an array of thousands of vaccine coated microprojections that perforate and deliver vaccine into the outer layers of the skin when applied with an applicator device.
Niren murthy, associate professor at georgia institute of technology, says the new particles represent a fairly large advance, though he says that more experiments are needed to show that they can elicit an immune response against human disease, in human subjects. Oct 05, 2017 efforts to rid the world of polio have taken another significant step, thanks to research led by university of queensland bioscience experts and funding from the world health organisation who. After graduation, christine wun bpharm sci hons form sci 2014 jumped at the opportunity to work for vaxxas, a brisbanebased company that is changing the face of vaccine delivery technology. Professor kendall heads a team responsible for the development of the nanopatch, a breakthrough technology that is a bit like a postage stamp. Forster ah, witham k, depelsenaire aci, veitch m, wells jw, wheatley a, et al. A fresh study of the nanopatch a microscopic vaccine delivery platform has shown the device more effectively combats. Engineered to directly deposit vaccine amongst dense population of key immune cells in the skin, developing an. The potential benefits of the technology suggest that further research and development of hdmaps is warranted.
A vaccine is a biological preparation that provides active acquired immunity to a particular disease. Nanopatch a new vaccination delivery method could replace needles and syringes and save millions of lives. The patches will be studied to evaluate their potential role as part of the worldwide efforts to eradicate polio. Awarded first class honours for immunology research project conducted on the nanopatch. Vaxxas is using micro needle technology to develop a new medical device for vaccine delivery at the university of queensland. In recognition of my innovation and translation, i have received numerous awards. A fresh study of the nanopatch a microscopic vaccine delivery platform has. During the two day event you can meet, network and do business with hundreds of professionals looking to find solutions, obtain answers, and buy the products and services they need to fulfil their formulation, development and manufacturing requirements. Many of his initial trials have been conducted in papua new guinea, which has one of the highest rates of hpv infections in the world but limited or no access to the current vaccine because of cost. We are extremely grateful to the who for providing funding to vaxxas pty ltd, the biotechnology company commercialising the nanopatch. An advanced platform that vaccinates by applying a patch to the skin for a few seconds. A vaccine typically contains an agent that resembles a diseasecausing microorganism and is often made from weakened or killed forms of the microbe, its toxins, or one of its surface proteins. Nanopatch polio vaccine success uq news the university of.
We previously demonstrated that using the nanopatch delivery system, an equivalent antigen specific igg was achieved compared to im with 100fold dose reduction 6. The company is working on boosting the performance of existing vaccines through a novel vaccine delivery technology called nanopatch. Jun 18, 20 kendall, who has launched vaxxas, a company to market his nanopatch microneedle patch, is focusing on delivering a human papillomavirus hpv vaccine. On the 23rd august vaxxas will present an overview of the company, the nanopatch technology and translation activities to date. In 2018 mark joined the australian national university, and serves as the founder and ceo of wearoptimo. Placed 6th in the university of queenslands school of biomedical science honours cohort, 2014. Vaxxas nanopatch technology aims to provide an optimized, differentiated needlefree vaccine delivery solution that safely and cost effectively amplifies vaccine efficacy. Homepage revolutionizing how we prevent and treat diseases. The nanopatch technology has been licensed to us based pharmaceutical company merck and co. Each nanopatch consists of a 16 mm 2 silicon base with 3364 microprojections 21, 025 cm. The support specifically assists preclinical studies and. Potent response of qs21 as a vaccine adjuvant in the skin. Vaxxas is developing a new medical device for vaccine delivery using a gamechanging micro needle technology nanopatchtm developed at the university of queensland.
Queensland biotechnology startup, vaxxas has formed a new partnership with queensland micro and nanotechnology centre qmnc at griffith university to help boost nanotechnology commercialisation. Nanopatch technology is being commercialised by vaxxas pty ltd, which has scaled the nanopatch from use in small models to prototypes for human use. Vaxxas hold patents over one of the world most exciting biotechnology products, the nanopatch, which is a safer, more reliable and durable delivery system for vaccines than needles. With the addition of qa to nanopatch, the dose reduction increased to 900fold when compared to unadjuvanted im 24. Biomedical translation fund invests in further development of total artificial heart device. Then, returning to australia as professor of biomedical engineering at the university of queensland, he invented the nanopatch, and in 2011 founded vaxxas to commercialise the nanopatch.
David hoey is the ceo and director of the vaxxas, a company working on enhancing the performance of existing and next generation vaccines through a novel vaccine delivery technology called. A vaccine typically contains an agent that resembles a diseasecausing microorganism and is often made from weakened or killed forms of. Engineered to directly deposit vaccine amongst dense population of key immune cells in the skin, developing an efficient and effective immune response. Nanopatch groups were represented by unadjuvanted, qs21 and qa a total antigen specific igg b igg1 and c igg2c induced by co. The nanopatch jet coating instrument is one of a series of. Efforts to rid the world of polio have taken another significant step. Safe, simple and needlefree vaccinations australia unlimited. Vaxxas hold patents over one of the world most exciting biotechnology products, the nanopatch, which is a safer, more reliable and durable delivery. Simona sarmiento medical typist capital pathology pty. Needlefree nanopatch technology developed at the university of queensland has been used to successfully deliver an inactivated poliovirus vaccine. Bioengineer developing needlefree nanopatch vaccines. Nanopatch vaccine breakthrough by the university of queensland. Nanopatch induced higher igg compared to im, with or without qs21. Vaxxas ceo mr david hoey said the first human vaccination studies are scheduled for this year.
Incorporated as a notforprofit foundation in 1971, and headquartered in geneva, switzerland, the forum is tied to no political. New study highlights the dangers of science denialism a recent outbreak of measles has been traced to one individual. Under the agreement, merck will pay vaxxas an undisclosed upfront fee and fund the firms research evaluating the potential of using the nanopatch platform for a merck vaccine candidate. Importantly, the particles also elicit a strong antibody response.
Invetech and vaxxas named recipients of the 2015 good. Moving away from melbourne was a big step, but the companys reputation and its revolutionary work in vaccine delivery technology were real. This included him performing roles in vaxxas pty ltd. Vaxxas has just signed an agreement with the world health organisation who to trial its nanopatch delivery system for polio vaccines, which the company hopes will progress the technology through. The institutes second director, professor alan rowan, commenced. Maryanne demasi discovers the nanopatch and its future potential. Vaxxas nanopatch jet coating instrument good design.
Vaxxas, a developer of a novel vaccine delivery technology called nanopatch, has agreed a research partnership with merck. Vaxxas nanopatch contains an ultrahigh density array of projections invisible to the naked human eye that are drycoated with vaccine. Israeli venture partnership launches new venture credit fund to invest in highgrowth technology companies. Vaxxas is a venture capital funded technology startup biotechnology company focused on enhancing the performance of existing and nextgeneration vaccines through its proprietary nanopatch. The distance between core research and influencing a change in clinical practice can sometimes stretch an entire career, but our goal is to provide resources to assist the researches based in. Nanopatch polio vaccine success uq news the university. The nanopatch is designed to place a tiny amount of vaccine just under the skin without the need for a needle jab. Incorporated as a notforprofit foundation in 1971, and headquartered in geneva, switzerland, the forum is tied to no political, partisan or national interests. Jul 11, 2016 nanopatch groups were represented by unadjuvanted, qs21 and qa a total antigen specific igg b igg1 and c igg2c induced by coadministering 6 ng of influenza antigen with qs21 at. This includes him performing roles in vaxxas pty ltd e.
Jul 27, 2017 queensland biotechnology startup, vaxxas has formed a new partnership with queensland micro and nanotechnology centre qmnc at griffith university to help boost nanotechnology commercialisation. Oct 05, 2017 efforts to rid the world of polio have taken another significant step. Development of stabilizing formulations of a trivalent. Vaxxas has pipeline projects with some of the largest vaccine manufacturers in the world as well as leading humanitarian organisations such as the world health. Because it delivers the active ingredient right to where it is needed, tests have. The who will also conduct clinical tests to determine the utility of the nanopatch for polio vaccinations. In 2014, vaxxas was selected as a world economic forum technology pioneer based on the potential of the nanopatch to improve health on a global scale. We work closely as a team and thrive in a dynamic, exciting, and engaging work environment. Simona sarmiento medical typist capital pathology pty ltd. Nanopatch is the vaccine delivery system for people who. The nanopatch is currently undergoing clinical trials. The nanopatch is comprised of an ultrahigh density array of very short projections invisible to the naked eye that are coated with vaccine. Safety, tolerability, and immunogenicity of influenza. Nov 19, 2014 the nextgeneration vaccine delivery system, created by vaxxas, is called the nanopatch and is the size of an adult thumbnail.
New study highlights the dangers of science denialism a recent outbreak of measles has been traced to one individual child a stark reminder of a public health crisis. Jan 10, 20 the nanopatch is designed to place a tiny amount of vaccine just under the skin without the need for a needle jab. Australian institute for bioengineering and nanotechnology. Polio vaccination with microneedle patches receives. Combinations of reducing agent 15mm gsh and 1mm cysteine, cyclodextrins 5% wv sbe. Nanopatch microprojections breach the stratum corneum and penetrate into the viable epidermis and dermis. Polio vaccination with microneedle patches receives funding. Clinical success and widespread use of the nanopatch against polio could help in the current campaign to eradicate the disease. Coordinates the university of queenslands australian institute for bioengineering and nanotechnology aibn was established init is one of four standalone research institutions at the university with more than 500 researchers, students and support staff. Vaxxas is developing an advanced platform for needlefree vaccine delivery.
Wearable technologies wt wearable technologies is the. Vaxess is building a diverse team of exceptional people to rapidly advance innovative therapies on the mimix platform. Professor mark kendall, an inaugural arc future fellow at the university of queensland, is a pioneer in needlefree immunisation technology that promises to eliminate the need for needles and syringes for vaccine delivery. Nanopatch is the vaccine delivery system for people who fear. The basics of the clinical trial pathway for a new vaccine delivery technology and the associated manufacturing and quality requirements will be discussed in a 1 hour seminar in the auditorium, followed by lunch in. The world economic forum is an independent international organization committed to improving the state of the world by engaging business, political, academic and other leaders of society to shape global, regional and industry agendas. Nanovaccines can prevent tropical parasitic diseases such as malaria and filarisis nanotherapeutics use lower dosages than systemic drugs, allowing lifesaving drugs to be used for young children nanoparticles can deliver therapeutic agents across the bloodbrain barrier to treat neural disorders such as alzheimers, parkinsons, and traumatic. Brisbane a biomedical engineering hub engineers australia. Bioengineer developing needlefree nanopatch vaccines reuters.
1410 106 1477 1412 979 84 27 75 1248 104 1162 583 1353 1133 229 344 958 1479 821 366 161 1447 834 139 454 1402 583 934 1305 454 21 999 1071 1471 807 241